2024 OUTLOOK: CHINA BIOPHARMA GLOBAL TRANSACTION INSIGHTS, TRENDS & ANALYSIS
The year 2023 witnessed significant milestones, including a substantial volume of cross-border transactions, with out-licensing deals surpassing in-licensing deals, signaling a shift in the balance of cross-border transactions. Key developments in oncology therapeutics underscored China’s contributions to cutting-edge treatments and collaborations. Notable FDA approvals further highlighted China’s increasing impact on global drug innovation and regulatory achievements.
In the evolving landscape of China’s biopharmaceutical industry, the outlook for 2024 appears promising, building upon the developments and trends observed in 2023.
Continued Cross-Border Deals
The anticipated rise in cross-border deals reflects sustained interest in China’s biopharma industry. Notably, the first M&A between China and MNSs may pave the way for further collaborative ventures, signaling potential opportunities for increased international partnerships.
Industry Influence and Collaboration
China’s growing influence in the global pharmaceutical and biotech markets is expected to continue, emphasizing strategic collaborations and value creation through partnerships.
Therapeutic Advancements
Oncology therapeutics, particularly advancements in ADCs and other innovative treatments, are likely to remain a focal point, potentially fostering global partnerships and advancements in healthcare. Furthermore, the increased focus on emerging technologies such as degrader antibody conjugates and bispecific ADCs is anticipated to shape the future of healthcare innovation and investment.
IPO Activity
The potential for e potential for an uptake in IPOs in the Chinese healthcare sector is driven by evolving market conditions and renewed investor interest, indicating a positive trajectory for the industry.
Outlook for 2024
Forecasts indicate a resurgence in cross-border transactions as fiscal budgets recover, potentially paving the way for incremental growth in in-licensing partnerships. This aligns with the persistent momentum of out-licensing activities, which are poised to continue their upward trend, signaling enduring enthusiasm for external collaborations and licensing.